[Federal Register Volume 88, Number 37 (Friday, February 24, 2023)]
[Notices]
[Pages 11926-11927]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-03846]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.


[[Page 11927]]


    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research.
    Date: March 20, 2023.
    Time: 12:00 p.m. to 1:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Sudhirkumar Udhavrao Yanpallewar, M.D., 
Scientific Review Officer, Scientific Review Branch, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
Bethesda, MD 20892, (301) 443-4577, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; HEAL Initiative: HEAL Data2Action--Innovation and 
Acceleration Projects, Phased Awards.
    Date: March 22, 2023.
    Time: 12:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Office of Extramural Policy, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
Bethesda, MD 20892, (301) 827-5843 [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Registry of Medical Cannabis Use and Health 
Outcomes.
    Date: March 24, 2023.
    Time: 11:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, 301 North Stonestreet Avenue, Bethesda, MD 
20892, (301) 827-5819, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Omnibus Topic 167: Cause of Death Elucidated (CODE) 
in Drug Overdose: Research and Development of New Postmortem 
Toxicology Screening Devices That Are Portable, Rapid, Accurate, 
Affordable, and Accessible.
    Date: March 30, 2023.
    Time: 11:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, 301 North Stonestreet Avenue, Bethesda, MD 
20892, (301) 827-5819, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: February 17, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-03846 Filed 2-23-23; 8:45 am]
BILLING CODE 4140-01-P